Comparative analysis of indocyanine green and technetium-99m for sentinel lymph node localization in breast cancer – institutional experience - Scorecard - MDSpire
Advertisement
Comparative analysis of indocyanine green and technetium-99m for sentinel lymph node localization in breast cancer – institutional experience
Clinical Scorecard: Evaluation of Indocyanine Green versus Technetium-99m for Sentinel Lymph Node Mapping in Breast Cancer: An Institutional Perspective
At a Glance
Category
Detail
Condition
Breast Cancer
Key Mechanisms
Sentinel lymph node biopsy (SLNB) using ICG fluorescence imaging versus Tc-99m radioisotope mapping.
Target Population
Patients with biopsy-confirmed ductal carcinoma in situ or clinically node-negative invasive breast cancer (T1–T3).
Care Setting
Department of Surgery, University of Debrecen Clinical Centre, Hungary.
Key Highlights
ICG fluorescence achieved a sentinel node detection rate of 90.6%.
Tc-99m achieved a detection rate of 97.1%.
No ICG-related complications or adverse events reported.
ICG offers a radiation-free alternative to conventional techniques.
Further multicenter studies are warranted for long-term outcomes.
Guideline-Based Recommendations
Diagnosis
Use SLNB as the standard staging approach in clinically node-negative breast cancer.
Management
Consider ICG fluorescence imaging as a safe and effective alternative to Tc-99m.
Monitoring & Follow-up
Monitor sentinel node detection rates and metastatic involvement.
Risks
Be aware of potential allergic reactions to blue dye in conventional techniques.
Patient & Prescribing Data
106 patients with breast cancer undergoing SLNB.
21.7% received neoadjuvant systemic therapy; 63.2% had breast-conserving surgery.
Clinical Best Practices
Adhere to standardized international SLNB protocols.
Utilize ICG for real-time visualization in lymphatic mapping.
